نتایج جستجو برای: nccn

تعداد نتایج: 961  

Journal: :AIDS 2018
Kimberly L Levinson David J Riedel Laureen S Ojalvo Wesley Chan Ana M Angarita Amanda N Fader Anne F Rositch

OBJECTIVE To evaluate gynecologic cancer treatments in HIV-infected women for adherence to National Comprehensive Cancer Network (NCCN) guidelines and to describe survival by adherence to guidelines. DESIGN Beyond cervical cancer, there are little data on treatment and outcomes for these women. This is a retrospective cohort study of HIV-infected women with gynecologic cancers. METHODS HIV-...

2018
Jia-Xiang Ye Xia Liang Jian Wei Jing Zhou Yu Liao Yu-Lei Lu Xia-Quan Tang An-Yu Wang Yong Tang

Objective: It is unknown whether the treatment provided to patients with stage II-IVB NPC in southern China adheres to the 2015 NCCN guidelines. Consequently, a retrospective analysis was conducted, in order to evaluate the compliance with NCCN guidelines and identify the areas for improvement. Methods: The present study was a retrospective study that included patients with stage II-IVB NPC in ...

Journal: :Journal of the National Comprehensive Cancer Network : JNCCN 2012
James L Mohler Andrew J Armstrong Robert R Bahnson Barry Boston J Erik Busby Anthony Victor D'Amico James A Eastham Charles A Enke Thomas Farrington Celestia S Higano Eric Mark Horwitz Philip W Kantoff Mark H Kawachi Michael Kuettel Richard J Lee Gary R MacVicar Arnold W Malcolm David Miller Elizabeth R Plimack Julio M Pow-Sang Mack Roach Eric Rohren Stan Rosenfeld Sandy Srinivas Seth A Strope Jonathan Tward Przemyslaw Twardowski Patrick C Walsh Maria Ho Dorothy A Shead

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Prostate Cancer provide multidisciplinary recommendations for the clinical management of patients with prostate cancer. These NCCN Guidelines Insights highlight notable recent updates. Abiraterone acetate is a first-in-class hormonal agent that represents a new standard of care for patients with metastatic castration-recurr...

2001
Peter L. Greenberg John M. Bennett

NCCN All recommendations are category 2A unless otherwise specified. See believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. NCCN To find clinical trials online at NCCN Member Institutions, click here: nccn.org/clinical_trials/physician.html. The NCCN Guidelines are a statement of evidence and consensus of t...

2014
Melinda B. Chu Jordan B. Slutsky Maulik M. Dhandha Brandon T. Beal Eric S. Armbrecht Ronald J. Walker Mark A. Varvares Scott W. Fosko

Recent guidelines from the American Joint Committee on Cancer (AJCC) and National Comprehensive Cancer Network (NCCN) have been proposed for the assessment of "high-risk" cutaneous squamous cell carcinomas (cSCCs). Though different in perspective, both guidelines share the common goals of trying to identify "high-risk" cSCCs and improving patient outcomes. Thus, in theory, both definitions shou...

Journal: :Journal of the National Comprehensive Cancer Network : JNCCN 2014
R Michael Tuttle Robert I Haddad Douglas W Ball David Byrd Paxton Dickson Quan-Yang Duh Hormoz Ehya Megan Haymart Carl Hoh Jason P Hunt Andrei Iagaru Fouad Kandeel Peter Kopp Dominick M Lamonica William M Lydiatt Judith McCaffrey Jeffrey F Moley Lee Parks Christopher D Raeburn John A Ridge Matthew D Ringel Randall P Scheri Jatin P Shah Steven I Sherman Cord Sturgeon Steven G Waguespack Thomas N Wang Lori J Wirth Karin G Hoffmann Miranda Hughes

These NCCN Guidelines Insights focus on some of the major updates to the 2014 NCCN Guidelines for Thyroid Carcinoma. Kinase inhibitor therapy may be used to treat thyroid carcinoma that is symptomatic and/or progressive and not amenable to treatment with radioactive iodine. Sorafenib may be considered for select patients with metastatic differentiated thyroid carcinoma, whereas vandetanib or ca...

Journal: :Journal of the National Comprehensive Cancer Network : JNCCN 2014
Andrew D Zelenetz

During his presentation at the NCCN 19th Annual Conference, Dr. Andrew D. Zelenetz reviewed the updates to the 2014 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Hodgkin's Lymphomas. Dr. Zelenetz first discussed the updates for diffuse large B-cell lymphoma (DLBCL), focusing primarily on the emergence of MYC-positive DLBCL; the limited role of imaging in early-stage di...

Journal: :Journal of the National Comprehensive Cancer Network : JNCCN 1979
B L Crue A Felsööry D Agnew M D Kamdar W Randle S Griffin R Sherman P Menard J J Pinsky

More than 30% of patients with cancer report chronic pain, which is an indication of both the frequency of cancer-related pain and the failure to optimally manage it. Although access to opioid analgesics has greatly improved over the past 25 years, much remains to be done for patients experiencing severe pain. Opioids are far from ideal analgesics, noted Dr. Robert A. Swarm at the recent NCCN 1...

2016
Aya Nakaya Shinya Fujita Atsushi Satake Takahisa Nakanishi Yoshiko Azuma Yukie Tsubokura Masaaki Hotta Hideaki Yoshimura Kazuyoshi Ishii Tomoki Ito Shosaku Nomura

To evaluate the National Comprehensive Cancer Network (NCCN) International Prognostic Index (IPI), we analyzed 284 patients treated with the combination of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in our institution in Japan. Their 5-year overall survival (OS) by risk level was 80.7%, 74.8%, 55.4% and 67.5% (P=0.005); and their 5-year progression-free survi...

Journal: :Journal of the National Comprehensive Cancer Network : JNCCN 2011
Robert J Morgan Ronald D Alvarez Deborah K Armstrong Barry Boston Robert A Burger Lee-May Chen Larry Copeland Marta Ann Crispens David Gershenson Heidi J Gray Perry W Grigsby Ardeshir Hakam Laura J Havrilesky Carolyn Johnston Shashikant Lele Ursula A Matulonis David M O'Malley Richard T Penson Steven W Remmenga Paul Sabbatini Russell J Schilder Julian C Schink Nelson Teng Theresa L Werner

Ovarian neoplasms consist of several histopathologic entities, and treatment depends on the specific tumor type. Epithelial ovarian cancer comprises most malignant ovarian neoplasms (~ 80%)1; however, other less-common pathologic subtypes must be considered in treatment guidelines. The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Ovarian Cancer discuss epithelial ovarian ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید